All Outputs (10)

Acceptability of chronic liver disease screening in a UK primary care setting: a qualitative evaluation (2020)
Journal Article
Knight, H., Harman, D., Morling, J. R., Aithal, G., Card, T., Guha, I. N., & Bains, M. (2020). Acceptability of chronic liver disease screening in a UK primary care setting: a qualitative evaluation. BMJ Open, 10(11), https://doi.org/10.1136/bmjopen-2020-041574

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. OBJECTIVES: The increasing incidence of chronic liver disease (CLD) in the UK may be attributed to a rise in... Read More about Acceptability of chronic liver disease screening in a UK primary care setting: a qualitative evaluation.

In severe alcoholic hepatitis, serum cytokeratin-18 fragments are diagnostic, prognostic and theragnostic biomarkers (2020)
Journal Article
Atkinson, S. R., Grove, J. I., Liebig, S., Astbury, S., Vergis, N., Goldin, R., …Aithal, G. P. (2020). In severe alcoholic hepatitis, serum cytokeratin-18 fragments are diagnostic, prognostic and theragnostic biomarkers. American Journal of Gastroenterology, 115(11), 1857-1868. https://doi.org/10.14309/ajg.0000000000000912

INTRODUCTION: Up to 40% of patients with severe alcoholic hepatitis (AH) die within 6 months of presentation, making prompt diagnosis and appropriate treatment essential. We determined the associations between serum keratin-18 (K18) and histologi... Read More about In severe alcoholic hepatitis, serum cytokeratin-18 fragments are diagnostic, prognostic and theragnostic biomarkers.

Late diagnosis of chronic liver disease in a community cohort (UK biobank): determinants and impact on subsequent survival (2020)
Journal Article
Innes, H., Morling, J., Aspinall, E. A., Goldberg, D. J., Hutchinson, S. J., & Guha, I. N. (2020). Late diagnosis of chronic liver disease in a community cohort (UK biobank): determinants and impact on subsequent survival. Public Health, 187, 165-171. https://doi.org/10.1016/j.puhe.2020.07.017

BACKGROUND: Chronic liver disease (CLD) is frequently diagnosed at a late stage when prognosis is poor. We aimed to determine the patient factors associated with a late CLD diagnosis and its subsequent impact on survival in order to support early dia... Read More about Late diagnosis of chronic liver disease in a community cohort (UK biobank): determinants and impact on subsequent survival.

Health related quality of life in individuals at high risk of chronic liver disease: Impact of a community diagnostic pathway (2020)
Journal Article
Tildesley, Z., Chalmers, J., Harris, R., West, J., Guha, I. N., & Morling, J. R. (2020). Health related quality of life in individuals at high risk of chronic liver disease: Impact of a community diagnostic pathway. Public Health In Practice, 1, https://doi.org/10.1016/j.puhip.2020.100033

Objectives: There is a lack of understanding of health related quality of life (HRQoL) in chronic liver disease (CLD). With the rising prevalence of alcohol and obesity driven CLD, and the increasing ability to screen for fibrosis, it is important to... Read More about Health related quality of life in individuals at high risk of chronic liver disease: Impact of a community diagnostic pathway.

Non?invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh type 2 diabetes study (2020)
Journal Article
Grecian, S. M., McLachlan, S., Fallowfield, J. A., Kearns, P. K., Hayes, P. C., Guha, I. N., …Strachan, M. W. (2020). Non‐invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh type 2 diabetes study. Liver International, 40(9), 2252-2262. https://doi.org/10.1111/liv.14590

Background The incidence of cirrhosis and hepatocellular carcinoma (HCC) is increased in Type 2 diabetes, primarily secondary to non‐alcoholic fatty liver disease (NAFLD). European guidelines recommend screening for NAFLD in Type 2 diabetes. America... Read More about Non?invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh type 2 diabetes study.

aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis (2020)
Journal Article
Fan, R., Papatheodoridis, G., Sun, J., Innes, H., Toyoda, H., Xie, Q., …Hou, J. (2020). aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. Journal of Hepatology, 73(6), 1368-1378. https://doi.org/10.1016/j.jhep.2020.07.025

© 2020 European Association for the Study of the Liver Background & Aims: Hepatocellular carcinoma (HCC) is the leading cause of death in patients with chronic hepatitis. In this international collaboration, we sought to develop a global universal HC... Read More about aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis.

Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis (2020)
Journal Article
Trivedi, P. J., Muir, A. J., Levy, C., Bowlus, C. L., Manns, M. P., Lu, X., …Hirschfield, G. M. (2021). Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis. Clinical Gastroenterology and Hepatology, 19(6), 1248-1257. https://doi.org/10.1016/j.cgh.2020.07.032

Background & Aims Serum alkaline phosphatase (ALP) and the enhanced liver fibrosis (ELF) score are used as endpoints in trials of patients with primary sclerosing cholangitis (PSC). We aimed to quantify inter- and intra-individual variation in level... Read More about Inter- and Intra-individual Variation, and Limited Prognostic Utility, of Serum Alkaline Phosphatase in a Trial of Patients With Primary Sclerosing Cholangitis.

Non-invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh Type 2 Diabetes Study (2020)
Journal Article
Grecian, S. M., McLachlan, S., Fallowfield, J. A., Kearns, P. K., Hayes, P. C., Guha, N. I., …Strachan, M. W. (2020). Non-invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh Type 2 Diabetes Study. Liver International, 40(9), 2252-2262. https://doi.org/10.1111/liv.14590

Background The incidence of cirrhosis and hepatocellular carcinoma (HCC) is increased in Type 2 diabetes, primarily secondary to non‐alcoholic fatty liver disease (NAFLD). European guidelines recommend screening for NAFLD in Type 2 diabetes. America... Read More about Non-invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh Type 2 Diabetes Study.

Genome-wide Association Study for Alcohol-related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1. (2020)
Journal Article
Innes, H., Buch, S., Hutchinson, S., Guha, I. N., Morling, J. R., Barnes, E., …Stickel, F. (2020). Genome-wide Association Study for Alcohol-related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1. Gastroenterology, 159(4), 1276-1289.e7. https://doi.org/10.1053/j.gastro.2020.06.014

Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved. BACKGROUND & AIMS: Little is known about genetic factors that affect development of alcohol-related cirrhosis. We performed a genome-wide association study (GWAS) of samp... Read More about Genome-wide Association Study for Alcohol-related Cirrhosis Identifies Risk Loci in MARC1 and HNRNPUL1..

FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study (2020)
Journal Article
Newsome, P. N., Sasso, M., Deeks, J. J., Paredes, A., Boursier, J., Chan, W., …Harrison, S. A. (2020). FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. The Lancet Gastroenterology & Hepatology, 5(4), 362-373. https://doi.org/10.1016/S2468-1253%2819%2930383-8

Background The burden of non-alcoholic fatty liver disease (NAFLD) is increasing globally, and a major priority is to identify patients with non-alcoholic steatohepatitis (NASH) who are at greater risk of progression to cirrhosis, and who will be ca... Read More about FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study.